Introduction
In 2015, a meeting was held in Rome under the auspices of the European AIDS Clinical Society (EACS) to revise current standards of care for HIV infection and Correspondence: Dr Justyna D. Kowalska [1] . In response to this, the EACS Eastern Europe Regional representatives Cristiana Oprea and Andrzej Horban began an initiative to organize a meeting with national representatives of this region. Countries not included in the CEE region, the so-called "neighbouring countries", were also invited to participate through a personal call from Deniz G€ okengin.
This Euroguidelines in Central and Eastern Europe (ECEE) conference was held in Warsaw and was officially endorsed by the EACS and the Medical University of Warsaw.
Aims and scope of the conference
The main aim of the ECEE conference was to review EACS guidelines implementation across CEE and neighbouring countries, and in particular to discuss national strategies for timely combination antiretroviral therapy (cART) initiation in response to changes introduced in October 2015 to the EACS guidelines. An expected outcome was to discuss and agree on a consensus statement called The Warsaw Declaration.
Methods
During the 2-day meeting, country-based presentations were given. Each day consisted of two parts: expert-based presentations and a workshop based on the input of regional experts and country representatives.
On the first day, the EACS guidelines on cART, comorbidities, standard of care and opportunistic infections were presented. This was followed by country representatives presenting national data. Information was provided in a structured manner based on a predefined template that each representative received prior to the meeting. Data collected onto the template were country epidemiology, surveillance, national strategy for treatment and prevention, standard of care and access to care and treatment.
On the second day, experts presented region-specific issues related to specific populations, namely injecting drug users (IDUs), children and adolescents, and women. The workshop included facilitated discussions around five themes: monitoring the epidemic, monitoring treatment efficacy and safety, how to start cART, resistance and HIV/hepatitis C virus (HCV) coinfection.
Each participant filled in a questionnaire on the use of HIV guidelines in their countries. Guidelines considered were EACS version 8.0 2015, World Health Organization (WHO) 2013, International Antiviral SocietyÀUSA (IAS-USA) Panel, Department of Health and Human Services (DHHS) guidelines, and European Centre for Disease Prevention and Control (ECDC) HIV testing guidelines. Three answers were possible: "yes", "to some extent" and "no". Participants were also asked if there were any national guidelines and when they had been most recently updated.
At the conclusion of the meeting, participants discussed and signed the Warsaw Declaration.
Main outcomes
In total, 16 CEE and neighbouring countries were represented at the conference: Albania, Armenia, Belarus, Croatia, Czech Republic, Estonia, Georgia, Hungary, Lithuania, Moldova, Poland, Romania, Russia, Serbia, Slovakia and Turkey. The conference programme and participant list is available at the EACS website (http:// www.eacsociety.org/conferences/eacs-partnerships/eceeconference-2016.html).
Diversity in national epidemics and their surveillance
An important part of the conference was devoted to discussing each country's situation in terms of HIV epidemiology and surveillance methods. The diversity in this region of Europe is particularly noticeable in the dynamics of the epidemic and the modalities of its control. HIV prevalence among the 16 represented countries from the region showed significant heterogeneity, ranging from a very high (Estonia, Georgia and Russia) to a very low prevalence (Albania, Croatia, Serbia and Slovakia) [2] [3] [4] [5] [6] . The most prevalent mode of transmission has shifted from injecting drug use (IDU) in the early 1990s to men who have sex with men (MSM) in the last decade in some countries (Poland, Czech Republic, Serbia and Croatia), while remaining quite stable in others (Estonia, Russia, Belarus and Romania) [7] [8] [9] [10] . In Albania, Armenia and Moldova, countries where the epidemic started in the 1990s, the predominant mode of HIV infection has been heterosexual transmission, with no significant evolution [11] . It is important to note that many countries report a high prevalence of "unknown" mode of infection, for example 56.7% in Turkey and 24.6% in Hungary [12, 13] .
Existing surveillance systems are not delivering effective outcome measures, such as the number of people diagnosed with HIV infection who are linked to and remain in care. In many countries, data collected by current surveillance systems are often either not in agreement with local cohort data or unavailable. Central registration is based on anonymous reporting, and thus is imprecise and vulnerable to any incorrect inputs. As an example, in Turkey in 2009 the main mode of HIV transmission was reported to be heterosexual (57.3%); however, in 2014 the information on transmission mode was not available for 56.7% of individuals [12] . Central, personalized registration is available in Albania, Belarus, Czech Republic, Estonia, Georgia, Lithuania, Romania, Russia and Slovakia. Some countries, such as Hungary, have launched a new online notification system for HIVpositive patients. The new online system is able to recognize and merge data from anonymous notification with those who are personalized in 2015.
Most countries report only AIDS-related deaths, and do not collect data on non-AIDS-related causes of death. Although data indicate an increasing trend of non-AIDSrelated deaths in the European region, there are probably differences between countries, depending on the characteristics of regional epidemics, such as tuberculosis in Eastern European countries [14, 15] . As a consequence, numbers of new HIV cases provided by most of the surveillance authorities are not reflecting the current number of people living with HIV. At the same time, experts from the CEE region and neighbouring countries participating in the conference expressed their concerns regarding difficulties in obtaining results from national cohorts and local data published in medical journals. It appears that not all national surveillance systems are delivering information that allows reliable evidence to inform epidemic control. Taking into account the necessity to base any future actions on real-life needs and the diversity in national HIV epidemics, it is crucial to allow regional data and local cohort studies to be available in a recognizable manner [16] [17] [18] [19] [20] [21] [22] . Moreover, if national surveillance systems plan to introduce a new notification approach for HIV case registration, national cohorts could work as quality control for collected data.
Organization of HIV care and treatment access Published reports suggest large differences between Eastern and Western Europe regarding systems of treatment and care for both HIV infection and tuberculosis. However, Central Europe and neighbouring countries are rarely studied in detail [1, [23] [24] [25] . It became evident during the conference that this region is unique as a consequence of large inter-country variabilities. The most pronounced differences are in systems of care, including approaches to linkage, retention and adherence assessment. Only four countries out of 16 have any routine practices established for assessment of linkage to care. The main obstacle is the lack of effective central registration allowing case identification, such as a reproducible, anonymous coding system. Personalized central registration is available in Albania, Czech Republic, Estonia, Georgia, Lithuania, Romania, Russia and Slovakia. Available cascades of care show large numbers of patients remaining without treatment access and/or viral suppression. In Georgia 28% and in Russia 19% of all diagnosed patients achieved viral suppression [3, 4] . However, if put on treatment, 81% of patients in Russian achieve viral suppression (defined as HIV RNA < 1000 HIV-1 RNA copies/mL during 12 month of cART). Compared with Western European countries, care continuums are poorer and are a key area for future improvement, especially in terms of access to treatment [26, 27] .
cART availability cART is currently available without restrictions in the majority of CEE countries, but with a defined threshold of CD4 cell count [5] . However, in the new EACS guidelines released in October 2015, initiation of cART should occur at the time of HIV diagnosis regardless of CD4 count. This is going to have a major impact on the number of patients eligible for treatment, especially in countries with a high incidence of HIV infection [5] . In order to manage this new burden, CEE and neighbouring countries require a new approach to negotiating both necessary funds from governments and lower drug prices from the pharmaceutical industry. Moreover, as a consequence of high pricing and slow processes for reimbursements in some areas of CEE, the newest antiretrovirals are only available with restrictions in some areas of CEE. For example, in Serbia integrase inhibitors or darunavir is available only for salvage therapies and tenofovir only for HIV/HBV coinfection [17] . Limitations in first-line cART choice exist also in other countries. In some countries, stock-outs of antiretroviral drugs are common, as a result of poor, convoluted procurement processes and a lack of focus on this important issue by relevant health authorities, insurance funds and governments. This makes EACS guidelines very difficult to implement and puts some patients at significant clinical risk.
Monitoring of treatment efficacy, safety and resistance testing Accessibility of tools to monitor treatment efficacy and safety was also discussed during the conference. In most participating countries there is access to laboratory measurements, such as lymphocyte CD4 counts and HIV RNA measurements, although some countries experience problems with continuity of supplies for regular assessments. In addition, tests for viral tropism or human leucocyte antigen (HLA) B5701 are not routinely available in some countries.
In the majority of CEE countries, resistance testing is available in terms of staff and laboratory facilities. However, because of the high costs of the test (approximately US$25-100 per test), many countries do not routinely perform resistance testing. Although EACS guidelines recommend resistance testing for all na€ ıve patients starting cART, this is difficult to achieve in the CEE region and neighbouring countries [28] . According to recently published data from the Strategy to Control SPREAD of HIV Drug Resistance study, which included 10 countries from the CEE region, the overall prevalence of transmitted drug resistance (TDR) among naive patients was 8.3% (7.2À9.5%) and did not change between 2008 and 2010 [29] . In the light of these results, not performing routine resistance testing in na€ ıve patients is likely to have a marginal impact on treatment efficacy in the current epidemiological situation.
It is important to note that, as a consequence of the high level of stigma and social discrimination in the CEE region and neighbouring countries, HIV clinics also treat HIV-positive patients for non-HIV-related health problems. Most of the HIV physicians in this region also treat patients for seasonal illnesses, chronic noncommunicable diseases and other physical health conditions associated with economic development. For obvious reasons, the available system of financing HIV care is unable to adequately bear such a burden in the longer term. In response to stigma, some countries are centralizing HIV care in order to provide wider coverage of health problems. This is in direct contrast to the model of HIV care preferred in high-income countries, where primary care is increasingly covering non-HIV-related health care. A good example is Croatia, where all HIV-positive persons are treated at the University Hospital for Infectious Diseases in Zagreb, or the KAOS system financed by public health insurance in three centres in Poland, which offers all-in-one care for HIV-infected patients. Such a model is also used in some Western European settings. However, this approach of isolating HIV care reduces opportunities for non-HIV specialists to gain experience in HIV care, almost certainly reducing HIV testing frequencies and marginalizing HIV-infected patients.
The utility of different HIV care guidelines
The utility of EACS and other guidelines was evaluated at the conference based on the responses provided on the conference questionnaire by country representatives.
A total of 24 delegates from 16 CEE and neighbouring countries returned the questionnaires. Twenty (83%) were primarily infectious diseases specialists, three were epidemiologists and one was a clinical pharmacologist. Data were analysed per country (Table 1) .
Participants from 14 (87%) of the countries declared that they used the EACS guidelines. The limitation for using the EACS guidelines highlighted by four countries was a lack of resources (Albania, Belarus, Georgia and Serbia). In the majority of countries (94%), other guidelines are also used. In 11 (69%) countries, national guidelines are available and in eight countries these have recently been updated. Half of the countries also use the WHO and DHHS guidelines, over one-third use ECDC HIV testing guidelines and one in five use IAS-USA Panel guidelines from 2012.
Conclusions
The main result of the conference was that participants discussed and agreed on the existing and emerging obstacles to controlling the HIV epidemic in the region, and this agreement was put in the form of a declaration signed by all participants. This declaration in its published form will serve as a supportive document for scaling up cART use in CEE and neighbouring countries. The statements provided in the declaration will also serve as action points for further ECEE Conference Group activities. Furthermore, the document is open to all persons who wish to support the declaration and they can do so by joining the next meetings of the group and signing it.
The future aims of the group are to strengthen the benchmarking of HIV clinical care in the region through close collaboration, both in clinical practice and in research, as well as to allow exchange of experiences and expertise.
It is planned to continue yearly meetings and to include all countries from the CEE region and neighbouring countries.
The Warsaw Declaration for provision of EACS Guidelines in Central and Eastern Europe
In recognition of the necessity to build regional capacity in improving HIV care and preventing HIV transmission, the undersigned hereby declare their will to promote programmes, projects and activities promoting the widespread use of antiretroviral treatment for HIV infection in the Central and Eastern Europe region and neighbouring countries, and to remain in conformity with the provisions of the EACS guidelines.
The undersigned wish to underline that the key role in the process of scaling up antiretroviral treatment, as the most effective strategy to reduce mortality/morbidity and to stop HIV transmission, belongs to governmental and policy-making agencies. Therefore, we call these stake-holders to action in supporting national capacity in this area by more concise and proactive fundraising and immediate allocation of already existing resources.
A signed version of the above declaration can be downloaded from the official EACS website (http:// www.eacsociety.org/conferences/meetingscollaborations/ ecee-conference-2016.html).
